dovalogo.png
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
September 30, 2019 02:00 ET | Dova Pharmaceuticals, Inc.
Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per share upon regulatory approval of DOPTELET® for chemotherapy-induced thrombocytopenia...
dovalogo.png
Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference
September 25, 2019 16:15 ET | Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...
dovalogo.png
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
September 03, 2019 16:30 ET | Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President & Chief Executive Officer, will present company...
dovalogo.png
Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019 16:15 ET | Dova Pharmaceuticals, Inc.
DURHAM, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the 2019...
dovalogo.png
Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results
August 06, 2019 07:00 ET | Dova Pharmaceuticals, Inc.
DOPTELET® (avatrombopag) approved by U.S. Food and Drug Administration (FDA) for treatment of chronic immune thrombocytopenia (ITP); commercial launch occurred mid-JulyDOPTELET approved by European...
dovalogo.png
Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019
July 30, 2019 16:15 ET | Dova Pharmaceuticals, Inc.
DURHAM, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, August 6, 2019 at 9:00 a.m. ET to discuss second quarter 2019...
dovalogo.png
Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP)
July 19, 2019 07:30 ET | Dova Pharmaceuticals, Inc.
DURHAM, N.C., July 19, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases...
dovalogo.png
Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
June 27, 2019 08:05 ET | Dova Pharmaceuticals, Inc.
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication Company to Host Conference Call at 9am EST DURHAM,...
dovalogo.png
Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
June 25, 2019 08:00 ET | Dova Pharmaceuticals, Inc.
-Approval Based on Positive Efficacy and Safety Data from Two Phase 3 Clinical Trials- -Company Intends to Partner for the European Commercialization of DOPTELET- DURHAM, N.C., June 25, 2019 ...
dovalogo.png
Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress
June 24, 2019 08:00 ET | Dova Pharmaceuticals, Inc.
DURHAM, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Company will present four abstracts with data from studies of avatrombopag in patients...